Patent details

EP3512525 Title: COMBINATION THERAPY WITH LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES

Basic Information

Publication number:
EP3512525
PCT Application Number:
US2017051723
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP178515847
PCT Publication Number:
WO2018053232
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
COMBINATION THERAPY WITH LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES
French Title of Invention:
PHYTOTHÉRAPIE AVEC DES OLIGONUCLÉOTIDES ANTISENS LIPOSOMAUX
German Title of Invention:
KOMBINATIONSTHERAPIE MIT LIPOSOMALEN ANTISENSE-OLIGONUKLEOTIDEN
SPC Number:

Dates

Filing date:
15/09/2017
Grant date:
27/07/2022
EP Publication Date:
24/07/2019
PCT Publication Date:
22/03/2018
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
27/07/2022
EP B1 Publication Date:
27/07/2022
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
15/09/2022
Expiration date:
15/09/2037
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
20/07/2022
 
 

Name:
Bio-Path Holdings, Inc.
Address:
4710 Bellaire Boulevard Suite 210, Bellaire, TX 77401, United States (US)

Inventor

Name:
ASHIZAWA, Ana Tari
Address:
United States (US)

Priority

1

Priority Number:
201662395680 P
Priority Date:
16/09/2016
Priority Country:
United States (US)

2

Priority Number:
201762487277 P
Priority Date:
19/04/2017
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/7088; A61K 31/711; A61P 35/02;

Publication

European Patent Bulletin

Issue number:
202230
Publication date:
27/07/2022
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages